The University of Southampton
University of Southampton Institutional Repository

Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome

Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome
Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome
The 8p11 myeloproliferative syndrome (EMS) is an aggressive, atypical stem cell myeloproliferative disorder associated with chromosome translocations that disrupt and constitutively activate FGFR1 by fusion to diverse partner genes. To explore the possibility of targeted therapy for EMS, we have investigated the use of TKI258, a multitargeted receptor tyrosine kinase inhibitor with activity against FGFR, VEGFR, PDGFR, FLT3, and KIT that is currently being assessed for the treatment of a variety of malignancies in phase 1 clinical studies. The viability of Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 was specifically inhibited by TKI258 with IC(50) values of 150 nM and 90 nM, respectively. Inhibition was accompanied by dose-dependent inhibition of phosphorylation of each fusion gene, ERK, and STAT5. TKI258 also specifically inhibited proliferation and survival of the FGFR1OP2-FGFR1-positive KG1 and KG1A cell lines, resulting in increased levels of apoptosis. Primary cells from EMS patients showed significant, dose-dependent responses in liquid culture and in methylcellulose colony assays compared with controls. This work provides evidence that targeted therapy may be beneficial for patients with EMS.
fibroblast growth factor, patients, laboratories, culture, phosphorylation, cell survival, human, genetics, type 1, cell line, protein, dna-binding proteins, inhibition, benzimidazoles, cell culture techniques, aged, humans, metabolism, tyrosine, proto-oncogene proteins c-bcr, cell proliferation, middle aged, quinolones, myeloproliferative disorders, oncogene proteins, pair 8, female, therapy, survival, male, syndrome, fusion, treatment, tumor, evaluation studies, transcription factors, apoptosis, pathology, pharmacology, receptor, activity, drug effects, growth, proto-oncogene proteins, proteins, chromosomes, research, adult, genes, protein kinase inhibitors, research support
0006-4971
3729-3734
Chase, A.F.H.
a40a09c2-3073-4655-ba0b-a802e34914b5
Cross, N.C.
6b31788a-9b23-4938-ace2-5610032377a3
Chase, A.F.H.
a40a09c2-3073-4655-ba0b-a802e34914b5
Cross, N.C.
6b31788a-9b23-4938-ace2-5610032377a3

Chase, A.F.H. and Cross, N.C. (2007) Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood, 110 (10), 3729-3734. (doi:10.1182/blood-2007-02-074286).

Record type: Article

Abstract

The 8p11 myeloproliferative syndrome (EMS) is an aggressive, atypical stem cell myeloproliferative disorder associated with chromosome translocations that disrupt and constitutively activate FGFR1 by fusion to diverse partner genes. To explore the possibility of targeted therapy for EMS, we have investigated the use of TKI258, a multitargeted receptor tyrosine kinase inhibitor with activity against FGFR, VEGFR, PDGFR, FLT3, and KIT that is currently being assessed for the treatment of a variety of malignancies in phase 1 clinical studies. The viability of Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 was specifically inhibited by TKI258 with IC(50) values of 150 nM and 90 nM, respectively. Inhibition was accompanied by dose-dependent inhibition of phosphorylation of each fusion gene, ERK, and STAT5. TKI258 also specifically inhibited proliferation and survival of the FGFR1OP2-FGFR1-positive KG1 and KG1A cell lines, resulting in increased levels of apoptosis. Primary cells from EMS patients showed significant, dose-dependent responses in liquid culture and in methylcellulose colony assays compared with controls. This work provides evidence that targeted therapy may be beneficial for patients with EMS.

Full text not available from this repository.

More information

Published date: 2007
Keywords: fibroblast growth factor, patients, laboratories, culture, phosphorylation, cell survival, human, genetics, type 1, cell line, protein, dna-binding proteins, inhibition, benzimidazoles, cell culture techniques, aged, humans, metabolism, tyrosine, proto-oncogene proteins c-bcr, cell proliferation, middle aged, quinolones, myeloproliferative disorders, oncogene proteins, pair 8, female, therapy, survival, male, syndrome, fusion, treatment, tumor, evaluation studies, transcription factors, apoptosis, pathology, pharmacology, receptor, activity, drug effects, growth, proto-oncogene proteins, proteins, chromosomes, research, adult, genes, protein kinase inhibitors, research support

Identifiers

Local EPrints ID: 59563
URI: https://eprints.soton.ac.uk/id/eprint/59563
ISSN: 0006-4971
PURE UUID: ef3edb62-e13c-4654-993e-3cef023f564a

Catalogue record

Date deposited: 02 Sep 2008
Last modified: 13 Mar 2019 20:30

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×